About
BioVentrix, Inc. is a clinical-stage medical device company based in Mansfield, Massachusetts. The company is dedicated to providing lifesaving therapies for patients with heart failure, focusing on minimally invasive treatments for left ventricular (LV) dilation, a common issue in ischemic heart failure. The flagship product, the Revivent™ System, supports a procedure called Less Invasive Ventricular Enhancement (LIVE®). This innovative approach uses myocardial micro-anchor implants to reconstruct and reduce the size of a dilated left ventricle, enhancing cardiac function. BioVentrix is currently conducting the ALIVE clinical study in the U.S., evaluating the safety and efficacy of the Revivent TC® system in heart failure patients with LV scarring. Led by Co-CEOs David Richmond and Steven Chartier, BioVentrix is privately funded and focuses on advancing its heart failure therapies through clinical research and regulatory pathways. The company aims to improve outcomes for heart failure patients and support cardiothoracic surgeons in their treatment efforts.
Technologies
Keywords
Company Information
- Employees20
- Founded2003
- Annual Revenue$19000000
- Total Funding$160012667
Location
120 Forbes Blvd, Mansfield, Massachusetts, United States, 02048-1150
